Lantern Pharma Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Lantern Pharma hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

1.3%

Rückkaufsrendite

Gesamte Aktionärsrendite	1.3%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von LTRN in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von LTRN gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Lantern Pharma Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von LTRN im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (LTRN)	n/a
Untere 25 % des Marktes (US)	1.3%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (LTRN) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von LTRN im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von LTRN im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von LTRN, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da LTRN keine Ausschüttungen gemeldet hat.

Lantern Pharma Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Lantern Pharma Inc. (NasdaqCM:LTRN) announces an Equity Buyback for $7 million worth of its shares.

Recent updates

Lantern Pharma Inc. Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Lantern Pharma Inc. to Report Q3, 2024 Results on Nov 07, 2024

Lantern Pharma's Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation in Glioblastoma from the Fda

Lantern Pharma Highlights Promising Preclinical Results of LP-184'S Synergy with Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson At Immuno-Oncology Summit 2024

Lantern Pharma Inc. to Report Q2, 2024 Results on Aug 08, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Lantern Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

Lantern Pharma Inc., Annual General Meeting, Jun 13, 2024

Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284

Lantern Pharma Inc. to Report Q4, 2023 Results on Mar 18, 2024

Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers

New minor risk - Share price stability

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company

Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma

Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting

Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Oncotarget Publishes New Data by Lantern Pharma Further Supporting Clinical Advancement of LP-284, A Novel Synthetic Lethal Drug Candidate for Non-Hodgkin's Lymphomas

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma Inc. Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

Lantern Pharma Inc. Receives Pre-IND Feedback from the FDA

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Lantern Pharma Inc. Announces Positive New Data for Its Drug Candidate LP-284 for Mantle Cell Lymphoma

Lantern Pharma Inc. Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate Lp-184 for Glioblastoma

Price target decreased to US$18.50

Lantern Pharma Inc. to Report Q3, 2022 Results on Nov 07, 2022

Lantern Pharma Inc. to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma Receives Food and Drug Administration Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Price target decreased to US$26.00

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Lantern Pharma Inc. Announces Leslie W. Kreis, Jr. Not to Stand for Reelection as A Director

Lantern Pharma Inc. to Report Q1, 2022 Results on May 03, 2022

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for Lp-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology

Lantern Pharma Inc. (NasdaqCM:LTRN) announces an Equity Buyback for $7 million worth of its shares.

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Price target increased to US$29.50

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Lantern Pharma: Drug Recycling With AI

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

Lantern Pharma Announces That RADR® Has Exceeded 4.6 Billion Datapoints

Lantern Pharma Inc. Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

Lantern Pharma Inc. Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma Inc. has completed a Follow-on Equity Offering in the amount of $60.00001 million.

New 90-day low: US$14.51

Lantern Pharma Inc. and AF Chemicals, LLC Enter into Second Addendum to Technology License Agreement

Lantern Pharma Announces Launch of Antibody Drug Conjugate (Adc) Program to Target Solid Tumors & Blood Cancers Through Agreement with Califia Pharma

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

Lantern: Early Stage 'Smart Drug' Discovery Company

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, A Next-Generation, Targeted DNA-Damaging Agent

New 90-day high: US$21.25

Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer

New 90-day high - US$19.24